Breaking Finance News

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has been upgraded to Sell in a statement by ValuEngine earlier today.

ValuEngine has upgraded Marinus Pharmaceuticals Inc (NASDAQ:MRNS) to Sell in a statement released on Tuesday June 20, 2017.

On 03/17/2017, Zacks Investment Research released a statement on Marinus Pharmaceuticals Inc (NASDAQ:MRNS) upped the target price from $0.00 to $1.75 that suggested an upside of 0.11%.

Having a price of $1.38, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) traded 2.24% higher on the day. With the last close down 131.63% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. MRNS has recorded a 50-day average of $2.81 and a two hundred day average of $1.77. Trade Volume was up over the average, with 5,463,767 shares of MRNS changing hands over the typical 1,313,110

Recent Performance Chart

Marinus Pharmaceuticals Inc (NASDAQ:MRNS)

Marinus Pharmaceuticals Inc has with a one year low of $0.82 and a one year high of $5.44 and has a total market value of $0.

A total of 5 equity analysts have released a ratings update on MRNS. Three equity analysts rating the company a strong buy, two equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $16.20.

Brief Synopsis About Marinus Pharmaceuticals Inc (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.